<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595996</url>
  </required_header>
  <id_info>
    <org_study_id>AAAP9262</org_study_id>
    <nct_id>NCT02595996</nct_id>
  </id_info>
  <brief_title>Propranolol Dose Escalation in Lymphedema in Patients</brief_title>
  <official_title>An Intra-patient Dose Escalation Study of Propranolol in Patients With Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the safety and efficacy of propranolol in the treatment of&#xD;
      patients with primary lymphedema. The primary goal is to assess patient tolerability of&#xD;
      increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and&#xD;
      signs in response to propranolol treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphatic malformations (LMs) arise from abnormal development of lymphatic vasculature.&#xD;
      Primary lymphedema is considered a form of LM. Recently, results in the investigators'&#xD;
      laboratory demonstrated that propranolol, a pan beta-adrenergic receptor (βAR) antagonist,&#xD;
      had cytotoxic and anti-proliferative effects against cells isolated from LM tissues.&#xD;
      Preliminary results from treating symptomatic LM patients with propranolol at a dose range&#xD;
      from 0.7-1mg/kg/day demonstrated a 70% positive response rate, with patients reporting&#xD;
      improvement in their symptoms.&#xD;
&#xD;
      Propranolol has been used for different indications for many years. Propranolol is accepted&#xD;
      for use in infants with hemangiomas and supraventricular tachycardia. Hemangeol was approved&#xD;
      by the FDA for use in infants with hemangiomas. However, βAR antagonists are not without&#xD;
      potential adverse effects, including hypotension, bradycardia, hypoglycemia, bronchospasms,&#xD;
      and sleep disturbances. FDA-approved dose range for treating hemangiomas in infants (&gt;5 weeks&#xD;
      old, &gt;2kg) ranged from 1-3mg/kg/day in divided doses. Propranolol doses of up to 4mg/kg/day&#xD;
      has been used for pediatric supraventricular tachycardia. Therefore, the investigator's&#xD;
      experience with propranolol use in LM patients have been at the low end of most accepted&#xD;
      clinical indications. The investigators propose to escalate propranolol dosages up to&#xD;
      3mg/kg/day in this study, well below the dose ranges currently used in clinical settings.&#xD;
&#xD;
      This dose range of 0.7-1mg/kg/day was chosen for LM patients as it was the low end of dose&#xD;
      range for infants treated with propranolol for problematic hemangiomas, a related vascular&#xD;
      anomaly. At this dose, no significant hemodynamic adverse effects were noted in LM patients.&#xD;
      However, when patients stopped propranolol or their dose fell below 0.7mg/kg/day, they&#xD;
      suffered rebound worsening of their symptoms. Moreover, inflammatory events such as&#xD;
      infections temporarily overcame the effects of 0.7-1mg/kg/day of propranolol. Thus, it is&#xD;
      unknown whether maximum propranolol efficacy was achieved at the current dose range. The&#xD;
      investigators propose to examine whether optimized propranolol usage for treatment of LM&#xD;
      patients has been achieved. The primary endpoint for this study is to ascertain whether LM&#xD;
      patients can tolerate higher doses of propranolol, as measured by known propranolol adverse&#xD;
      effects and patient-reported symptoms. A secondary endpoint will address whether&#xD;
      patient-reported LM symptoms and quality of life are improved with higher doses of&#xD;
      propranolol; objective findings such as LM size on physical examination and imaging studies&#xD;
      will be analyzed as well. In addition, LM tissue biopsies will acquired from patients before&#xD;
      and after propranolol treatment for further analyses of disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">October 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients That Tolerated Propranolol</measure>
    <time_frame>8 weeks</time_frame>
    <description>To assess whether patients tolerated propranolol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Improved Quality of Life Based on Self-reported Questionnaires</measure>
    <time_frame>8 weeks</time_frame>
    <description>To assess subjective lymphedema symptoms improvements only - whether patients' general quality of life symptoms improved on propranolol treatment by self-reported questionnaires (SF 36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Decreased Fluid Retention by Weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>To assess whether patients' lymphedema signs are improved on propranolol by weight (BMI kg/m^2) - objective signs of improvement of their lymphedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Lower Limb Discrepancy</measure>
    <time_frame>8 weeks</time_frame>
    <description>To assess whether patients' lymphedema signs are improved on propranolol by limb girth discrepancy measurement (%) - objective signs of improvement of their lymphedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Decreased Fluid Retention on MRI</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>To assess whether patients' lymphedema signs are improved on propranolol - the decrease in fluid retention will be calculated by the measurement of fat (a number) divide by the measurement of fluid (a number) to yield a ratio - if a patient has a lower ratio at 8 weeks than at baseline, they will be reported in this category.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Primary Lymphedema</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given propranolol in escalating doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary lymphedema&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Adequate functional status: Karnofsky &gt;50% (&gt;age 16), Lanky &gt;50 (&lt;age 16),&#xD;
&#xD;
          -  No prior therapy within 4 weeks of enrollment&#xD;
&#xD;
          -  Adequate bone marrow, renal function, cardiac, and pulmonary function, negative&#xD;
             pregnancy test (for women).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary lymphedema&#xD;
&#xD;
          -  Patients already receiving other investigational drugs&#xD;
&#xD;
          -  Patients with known contraindications to receiving propranolol&#xD;
&#xD;
          -  Other medical comorbidities including but not limited to: pheochromocytoma,&#xD;
             bradycardia, bronchospasm/reactive airway disease, decompensated heart failure, heart&#xD;
             block, ongoing active infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June K. Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>June Wu</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02595996/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Tolerated Propranolol</title>
        <description>To assess whether patients tolerated propranolol</description>
        <time_frame>8 weeks</time_frame>
        <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Tolerated Propranolol</title>
          <description>To assess whether patients tolerated propranolol</description>
          <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Improved Quality of Life Based on Self-reported Questionnaires</title>
        <description>To assess subjective lymphedema symptoms improvements only - whether patients' general quality of life symptoms improved on propranolol treatment by self-reported questionnaires (SF 36)</description>
        <time_frame>8 weeks</time_frame>
        <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Improved Quality of Life Based on Self-reported Questionnaires</title>
          <description>To assess subjective lymphedema symptoms improvements only - whether patients' general quality of life symptoms improved on propranolol treatment by self-reported questionnaires (SF 36)</description>
          <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Decreased Fluid Retention by Weight</title>
        <description>To assess whether patients' lymphedema signs are improved on propranolol by weight (BMI kg/m^2) - objective signs of improvement of their lymphedema</description>
        <time_frame>8 weeks</time_frame>
        <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Decreased Fluid Retention by Weight</title>
          <description>To assess whether patients' lymphedema signs are improved on propranolol by weight (BMI kg/m^2) - objective signs of improvement of their lymphedema</description>
          <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Lower Limb Discrepancy</title>
        <description>To assess whether patients' lymphedema signs are improved on propranolol by limb girth discrepancy measurement (%) - objective signs of improvement of their lymphedema</description>
        <time_frame>8 weeks</time_frame>
        <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Lower Limb Discrepancy</title>
          <description>To assess whether patients' lymphedema signs are improved on propranolol by limb girth discrepancy measurement (%) - objective signs of improvement of their lymphedema</description>
          <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Decreased Fluid Retention on MRI</title>
        <description>To assess whether patients' lymphedema signs are improved on propranolol - the decrease in fluid retention will be calculated by the measurement of fat (a number) divide by the measurement of fluid (a number) to yield a ratio - if a patient has a lower ratio at 8 weeks than at baseline, they will be reported in this category.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Decreased Fluid Retention on MRI</title>
          <description>To assess whether patients' lymphedema signs are improved on propranolol - the decrease in fluid retention will be calculated by the measurement of fat (a number) divide by the measurement of fluid (a number) to yield a ratio - if a patient has a lower ratio at 8 weeks than at baseline, they will be reported in this category.</description>
          <population>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Patients will be given propranolol in escalating doses&#xD;
Propranolol: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>June K. Wu, MD</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>212-342-3704</phone>
      <email>jw92@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

